Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease
Abstract
1. Introduction
2. Methods
2.1. Study Participants
2.2. Quality-of-Life Metrics
2.3. Trial End Points
2.4. Statistical Analysis
3. Results
3.1. Baseline Characteristics
3.2. Physical Function
3.3. Role Physical
3.4. Body Pain
3.5. General Health
3.6. Vitality
3.7. Social Functioning
3.8. Role Emotional
3.9. Mental Health
3.10. Haemoglobin (Hb), Serum Ferritin (SF) and Transferrin Saturation (TSAT)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kovesdy, C.P. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 2022, 12, 7–11. [Google Scholar] [CrossRef]
- Kirkman, D.L.; Bohmke, N.; Carbone, S.; Garten, R.S.; Rodriguez-Miguelez, P.; Franco, R.L.; Kidd, J.M.; Abbate, A. Exercise intolerance in kidney diseases: Physiological contributors and therapeutic strategies. Am. J. Physiol. Ren. Physiol. 2021, 320, F161–F173. [Google Scholar] [CrossRef]
- Agarwal, A.K. Iron metabolism and management: Focus on chronic kidney disease. Kidney Int. Suppl. 2021, 11, 46–58. [Google Scholar] [CrossRef]
- Neidlein, S.; Wirth, R.; Pourhassan, M. Iron deficiency, fatigue and muscle strength in older hospitalised patients. Eur. J. Clin. Nutr. 2021, 75, 456–463. [Google Scholar] [CrossRef]
- Alnuwaysir, R.I.S.; Hoes, M.F.; van Veldhuisen, D.J.; van der Meer, P.; Beverborg, N.G. Iron deficiency in heart failure: Mechanisms and pathophysiology. J. Clin. Med. 2022, 11, 125. [Google Scholar] [CrossRef]
- Bhandari, S. Oxidative stress and mitochondrial function in experimental CKD. Front. Biosci. Landmark Ed. 2021, 26, 442–464. [Google Scholar] [CrossRef]
- Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric carboxymaltose in patients with heart failure and iron deficiency (FAIR-HF). N. Engl. J. Med. 2009, 361, 2436–2448. [Google Scholar] [CrossRef] [PubMed]
- Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Anaemia in CKD. Public Review Draft. 2024. Available online: https://www.ukkidney.org/sites/default/files/FINAL%20VERSION%20-%20%20UKKA%20ANAEMIA%20OF%20CKD%20GUIDELINE%20-%20Sept%202024.pdf (accessed on 26 July 2025).
- Bhandari, S.; Allgar, V.; Lamplugh, A.; Macdougall, I.; Kalra, P.A. Intravenous ferric derisomaltose in iron-deficient but non-anaemic CKD patients: A multicentre randomised controlled trial. BMC Nephrol. 2021, 22, 115. [Google Scholar] [CrossRef]
- Brazier, J.E.; Harper, R.; Jones, N.M.; O’Cathain, A.; Thomas, K.J.; Usherwood, T.; Westlake, L. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992, 305, 160–164. [Google Scholar] [CrossRef] [PubMed]
- Bhandari, S.; Sebastian, S.; Oliveira, B.; Mikhail, A.; Brooks, O.; Bryant, G.; Willicombe, M.; Baines, R.; Alldridge, L.; Haslam-England, S. UK Kidney Association clinical practice guideline: Update of anaemia of chronic kidney disease. BMC Nephrol. 2025, 26, 193. [Google Scholar] [CrossRef] [PubMed]
- Bhandari, S.; Kalra, P.A.; Berkowitz, M.; Belo, D.; Thomsen, L.L.; Wolf, M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transpl. 2021, 36, 111–120. [Google Scholar] [CrossRef]
- Sharma, S.; Kalra, D.; Rashid, I.; Mehta, S.; Maity, M.K.; Wazir, K.; Gupta, S.; Ansari, S.A.; Alruqi, O.S.; Khan, R.; et al. Assessment of health-related quality of life in chronic kidney disease patients: A hospital-based cross-sectional study. Medicina 2023, 59, 1788. [Google Scholar] [CrossRef]
- Ware, J.E., Jr.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 1992, 30, 473–483. [Google Scholar] [CrossRef]
- Finch, C.A.; Miller, L.R.; Inamdar, A.R.; Person, R.; Seiler, K.; Mackler, B. Iron deficiency in the rat: Physiologic and biochemical studies of muscle dysfunction. Am. J. Clin. Nutr. 1976, 29, 287–295. [Google Scholar] [CrossRef]
- Nuhu, F.; Seymour, A.M.; Bhandari, S. Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. Antioxidants 2019, 8, 498. [Google Scholar] [CrossRef] [PubMed]
- Ponikowski, P.; van Veldhuisen, D.J.; Comin-Colet, J.; Ertl, G.; Komajda, M.; Mareev, V.; McDonagh, T.; Parkhomenko, A.; Tavazzi, L.; Levesque, V.; et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 2015, 36, 657–668. [Google Scholar] [CrossRef] [PubMed]
- Greenwood, S.A.; Oliveira, B.A.; Asgari, E.; Ayis, S.; Baker, L.A.; Beckley-Hoelscher, N.; Goubar, A.; Banerjee, D.; Bhandari, S.; Chilcot, J.; et al. A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD. Kidney Int. Rep. 2023, 8, 1496–1505. [Google Scholar] [CrossRef] [PubMed]
- Paul, R.; Cleland, J.; Petrie, M.; Thomson, E.A.; Kalra, P.A.; Squire, I.B.; Ahmed, F.Z.; Al-Mohammad, A.; Cowburn, P.J.; Foley, P.W.X.; et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022, 400, 2199–2209. [Google Scholar]
- Greenwood, S.A.; Beckley-Hoelscher, N.; Asgari, E.; Ayis, S.; Baker, L.A.; Banerjee, D.; Bhandari, S.; Bramham, K.; Chilcot, J.; Burton, J.; et al. The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: Study design and baseline data for a multicentre prospective double-blind randomised controlled trial. BMC Nephrol. 2022, 23, 268. [Google Scholar] [CrossRef]
- Pantopoulos, K. Oral iron supplementation: New formulations, old questions. Haematologica 2024, 109, 2790–2801. [Google Scholar] [CrossRef]
- Auerbach, M.; Henry, D.; DeLoughery, T.G. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. Am. J. Hematol. 2021, 96, 727–734. [Google Scholar] [CrossRef] [PubMed]
- Sinclair, R.C.F.; Nadaraja, S.; Kennedy, N.A.; Wakatsuki, M.; Bhandari, S. Real-world experience of intravenous iron isomaltoside: Safety and efficacy reporting in the UK. Sci. Rep. 2022, 12, 18859. [Google Scholar] [CrossRef] [PubMed]
Inclusion and Exclusion Criteria of Iron and Heart Study | |
---|---|
Inclusion | Exclusion |
Patients with established CKD (Stages 3b-5) not on dialysis | Pregnancy or breast feeding |
Resting BP ≤ 160/90 mmHg | Weight ≤ 50 kg |
Aged 18–80 years | Known allergy to iron therapy |
Serum ferritin < 100 μg/L; AND/OR transferrin saturation ≤ 20% | Haemochromatosis or history of acquired iron overload |
Haemoglobin ≥ 110 g/L AND ≤150 g/L | Parenteral iron received within previous 6 weeks |
CRP > 50 mg/L | |
Active infection | |
Current therapy with ESA agents | |
Patients with atrial fibrillation | |
Patients with solid organ cancer | |
Patients with known haemoglobinopathy, myelodysplasia or myeloma | |
Patients with musculoskeletal disease, who the investigator deems unable to carry out the 6-min walking test. |
Mapping of SF-36 Domains | ||||
---|---|---|---|---|
Domain | Number of Items | Item Numbers | Description | All Questions |
Physical Function | 10 | Q3a–Q3j | Assesses limitations in physical activities such as walking, climbing stairs, and carrying groceries (Q3a–Q3j). | Q3a–Q3j: Moderate activities, climbing stairs, bending/kneeling, walking various distances, bathing/dressing, lifting groceries. |
Role Physical | 4 | Q4a–Q4d | Evaluates problems with work or daily activities due to physical health (Q4a–Q4d). | Q4a–Q4d: Cut down time spent on work, accomplished less, limited in kind of work, difficulty performing work due to physical health. |
Body Pain | 2 | Q7, Q8 | Measures pain intensity and interference with normal work (Q7, Q8). | Q7, Q8: Pain intensity in past 4 weeks; pain interference with normal work including both outside the home and housework. |
General Health | 5 | Q1, Q11a–Q11d | Captures general perceptions of health, including current state and future expectations (Q1, Q11a–Q11d). | Q1, Q11a–Q11d: Self-rated general health, health is excellent, health is likely to get worse, health compared to others, getting sick easier than others. |
Vitality | 4 | Q9a, Q9e, Q9g, Q9i | Assesses energy and fatigue levels over recent time (Q9a, Q9e, Q9g, Q9i). | Q9a, Q9e, Q9g, Q9i: Felt full of life, had a lot of energy, felt tired, felt worn out. |
Social Functioning | 2 | Q6, Q10 | Evaluates interference of health problems with social activities (Q6, Q10). | Q6, Q10: Interference with social activities due to physical or emotional problems; time spent on social activities. |
Role Emotional | 3 | Q5a–Q5c | Measures difficulties in role functioning due to emotional problems (Q5a–Q5c). | Q5a–Q5c: Cut down amount of time on work, accomplished less, did work less carefully due to emotional problems. |
Mental Health | 5 | Q9b, Q9c, Q9d, Q9f, Q9h | Assesses emotional well-being and psychological distress (Q9b, Q9c, Q9d, Q9f, Q9h). | Q9b, Q9c, Q9d, Q9f, Q9h: Felt nervous, felt so down nothing could cheer you up, felt calm and peaceful, felt downhearted and blue, felt happy. |
Baseline Characteristics of Participants | ||||
---|---|---|---|---|
Total (n = 54) | FDI (n = 26) | Placebo (n = 28) | p-Value | |
Age (years) | 59.6 (11.7) | 61.6 (10.1) | 57.8 (12.9) | >0.05 |
Range | 32–78 | 37–78 | 32–78 | |
Sex, n (%) | ||||
Male | 26 (49%) | 11 (42.3%) | 15 (53.6%) | >0.05 |
Female | 27 (51%) | 14 (53.8%) | 13 (46.4%) | >0.05 |
Unknown | 1 | 1 | 0 | |
Ethnicity, n (%) | ||||
White | 42 (78%) | 19 (73.1%) | 23 (82.1%) | >0.05 |
Asian | 3 (5%) | 1 (3.8%) | 2 (7.1%) | >0.05 |
Black | 4 (7%) | 4 (15.4%) | 3 (10.7%) | >0.05 |
Mixed Race | 1 (2%) | 1 (3.8%) | 0 (0%) | >0.05 |
Unknown/Other | 1 (2%) | 1 (3.8%) | 0 (0%) | >0.05 |
Smoker, n (%) | ||||
Current | 5 (9%) | 1 (3.8%) | 4 (14.3%) | >0.05 |
Previous | 17 (32%) | 8 (30.8%) | 9 (32.1%) | >0.05 |
No | 32 (59%) | 17 (65.4%) | 15 (53.6%) | >0.05 |
BMI (kg/m2) | 30.3 (6.5), n = 53 | 30.7 (6.8) | 30.0 (6.4) | >0.05 |
Serum Ferritin (µg/L) | 66.3 (44.1), n = 53 | 64.2 (29.1) | 68.4 (55.3) | 0.195 |
TSAT (%) | 20.1 (7.4), n = 53 | 22.3 (8.8) | 19.7 (5.6) | <0.001 |
Haemoglobin (g/L) | 128.7 (10.1), n = 54 | 131 (7.4), n = 26 | 126.6 (11.8), n = 28 | <0.001 |
Serum Creatinine (µmol/L) | 186.7 (58.6), n = 54 | 167 (40.2), n = 26 | 204.9 (67.3), n = 28 | <0.001 |
eGFR (mL/min/1.73 m2) | 31.1 (9.6), n = 54 | 33.2 (9.3), n = 26 | 29.1 (9.6), n = 28 | >0.05 |
Cystatin C (mg/L) | 2.2 (0.6), n = 52 | 2.1 (0.5), n = 26 | 2.4 (0.6), n = 26 | >0.05 |
uACR (mg/mmol) | 60.9 (133.3), n = 26 | 26.9 (40.1), n = 13 | 94.8 (181.4), n = 13 | >0.05 |
uPCR (mg/mmol) | 83.8 (128.4), n = 40 | 51.9 (59.3), n = 19 | 112.7 (164.8), n = 21 | >0.05 |
CRP (mg/L) | 5.0 (4.4), n = 53 | 6.3 (5.5), n = 26 | 3.8 (2.4), n = 27 | >0.05 |
Serum Albumin (g/L) | 39.8 (5.6) | 40.8 (4.2) | 38.8 (6.9) | >0.05 |
Platelet Count (×109/L) | 235 (58.9) | 226 (52.4) | 243 (64.1) | >0.05 |
Phosphate (mmol/L) | 1.2 (0.2) | 1.1 (0.2) | 1.2 (0.2) | >0.05 |
NT pro BNP (ng/L) | 4852.0 (12,684.4), n = 51 | 4225.0 (8819.5), n = 25 | 5454.0 (15,695.0), n = 26 | >0.05 |
PWV (m/s) | 8.3 (3.2), n = 54 | 8.3 (2.8), n = 26 | 8.3 (3.6), n = 28 | >0.05 |
AiX (%) | 24.2 (10.7), n = 54 | 25.4 (10.7), n = 26 | 24.1 (10.8), n = 28 | >0.05 |
Change in Haemoglobin, Ferritin, and Transferrin Saturation over Time | ||||
---|---|---|---|---|
Timepoint | FDI (n = 26) | Placebo (n = 28) | p Value | |
Haemoglobin (g/L) | Baseline | 131.0 (7.4) | 126.5 (11.8) | — |
1 month | 132.7 (7.2) | 125.5 (12.8) | 0.195 | |
3 months | 134.7 (8.9) | 126.2 (12.4) | 0.152 | |
Serum Ferritin (µg/L) | Baseline | 64.2 (29.1) | 68.4 (55.3) | — |
1 month | 266.0 (105.8) | 70.5 (55.8) | <0.001 | |
3 months | 234.4 (105.3) | 69.1 (59.8) | <0.001 | |
TSAT (%) | Baseline | 22.3 (8.8) | 19.7 (5.6) | — |
1 month | 29.6 (9.5) | 19.1 (7.1) | <0.001 | |
3 months | 26.4 (10.5), n = 21 | 18.0 (6.8), n = 23 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jafri, A.; Youlden, C.; Spencer, S.; Bhandari, S. Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease. Biomedicines 2025, 13, 1860. https://doi.org/10.3390/biomedicines13081860
Jafri A, Youlden C, Spencer S, Bhandari S. Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease. Biomedicines. 2025; 13(8):1860. https://doi.org/10.3390/biomedicines13081860
Chicago/Turabian StyleJafri, Alisha, Charlotte Youlden, Sebastian Spencer, and Sunil Bhandari. 2025. "Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease" Biomedicines 13, no. 8: 1860. https://doi.org/10.3390/biomedicines13081860
APA StyleJafri, A., Youlden, C., Spencer, S., & Bhandari, S. (2025). Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease. Biomedicines, 13(8), 1860. https://doi.org/10.3390/biomedicines13081860